companies / temperobio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 76,958,45777.0M | ○ |
|---|---|---|
| founded | null | |
| hq | OAKLAND, CA | |
| industry | unknown | |
| stage | null |
Tempero Bio is a clinical-stage biopharma developing TMP-301, an oral mGluR5 modulator, to treat substance use disorders like cocaine and alcohol addiction. It serves patients with addiction and their clinicians, advancing into Phase 2. Its edge is dampening rather than blocking glutamate signaling, validated by PET occupancy.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-11-04 | Funding round | 76,958,45777.0M | null | ○ |
Google Cloud CDN, Sentry, Partytown, Vercel Speed Insights, WebsiteBuilder, Wix, Google Cloud, React, lodash .
| fact | status | src |
|---|---|---|
| Funding round, $77.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $77.0M, 2025-11-04 → Funding round, $77.0M, 2025-11-04, ○ 2026-05-08 | latest_round | seed, $77.0M, 2025-11-04 → Funding round, $77.0M, 2025-11-04 | ○ 2026-05-08 |
Records begin 2026-09-24. all_changes